# A Study to Learn About the Awareness and Knowledge That Doctors Have About the Safety and Safe Use Information for Androcur and Other Cyproterone Acetate Treatments in Europe

> **NCT04925180** · — · COMPLETED · sponsor: **Bayer** · enrollment: 600 (actual)

## Conditions studied

- Signs of Androgenisation in Women, e.g. Hirsutism, Androgenetic Alopecia, Acne and Seborrhea
- Hypersexuality in Men
- Sexual Deviations in Men
- Prostate Cancer

## Interventions

- **DRUG:** Cyproterone Acetate (Androcur, BAY94-8367)

## Key facts

- **NCT ID:** NCT04925180
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-18
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 600 (ACTUAL)
- **Last updated:** 2022-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04925180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04925180, "A Study to Learn About the Awareness and Knowledge That Doctors Have About the Safety and Safe Use Information for Androcur and Other Cyproterone Acetate Treatments in Europe". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04925180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*